Oxaliplatin-related acute myelogenous leukemia

Oncologist

Volumn 11, Issue 3, 2006, Pages 261-262

  Carneiro, Benedito A ^a   Kaminer, Lynne ^a,c   Eldibany, Mohammed ^b   Sreekantaiah, Chandrika ^d   Kaul, Karen ^b   Locker, Gershon Y ^a,b,e  

^a Kellogg Cancer Care Center   (United States)

^b Evanston Northwestern Healthcare ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Dianon Systems   (United States)

^e EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Acute myelogenous leukemia; Chemotherapy side effects; Colon adenocarcinoma therapy; Oxaliplatin; Therapy related leukemia

Indexed keywords

BEVACIZUMAB; CYTARABINE; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; OXALIPLATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADENOCARCINOMA; ADULT; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CAUSE OF DEATH; CECUM CANCER; CHROMOSOME 20; CHROMOSOME 21; CHROMOSOME 3; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME REARRANGEMENT; COLON CANCER; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; OVARY METASTASIS; PANCYTOPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRISOMY 8;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CECAL NEOPLASMS; CHROMOSOME DELETION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; OMENTUM; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SIGMOID NEOPLASMS; TRISOMY;

EID: 33645073920     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-3-261     Document Type: Article

References (7)

1. Rund D, Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology 2004;9:179-187.
2. Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 2005;352:1591-1594.
3. Merrouche Y, Mugneret F, Cahn JY. Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer. Ann. Oncol 2005 Nov 17; [Epub ahead of print].
4. Hashimoto H, Chatterjee S, Berger NA. Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1995;1:369-376.
5. Nakamori Y, Miyazaki M, Tominaga T et al. Therapy-related erythroleukemia caused by the administration of UFT and mitomycin C in a patient with colon cancer. Int J Clin Oncol 2003;8:56-59.
6. Takeyama K, Seto M, Uike N et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000;71:144-152.
7. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.